The vaccination status and adverse effects of COVID-19 vaccine among pregnant women in Japan in 2021.
COVID-19
adverse reaction
mRNA vaccine
pregnancy
vaccination
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
22
03
2022
received:
24
02
2022
accepted:
27
04
2022
pubmed:
11
5
2022
medline:
7
7
2022
entrez:
10
5
2022
Statut:
ppublish
Résumé
To investigate the vaccination status and adverse reactions to the COVID-19 vaccine among pregnant women in Japan, we conducted an online questionnaire survey from October 5 to November 22, 2021. The number of participants in the online survey was 6576. Of the participants, 4840 (73.6%) were vaccinated twice, and 557 (8.5%) were vaccinated once. A total of 1179 (17.9%) responders had never been vaccinated against COVID-19. The most frequent adverse reaction was local pain at the injection site. The incidence of local adverse reactions was almost identical after the first and the second vaccinations, while systemic reactions, such as fever and fatigue/malaise, and adverse reactions outside the vaccination site such as headache and arthralgia, were more frequent after the second vaccination than after the first vaccination. Regarding the obstetrical complications, uterine tension and/or contraction was observed in 1.65% of the pregnant women after the first vaccination and in 2.98% after the second vaccination, and uterine pain appeared in 1.06% of the pregnant women after the second vaccination. However, serious symptoms, such as hemorrhage, decreased fetal movement, edema, increased blood pressure, and amniorrhexis, were seen in less than 1% of vaccinated women after both the first and second vaccinations. This study clarified the characteristics of vaccination, adverse reactions, and obstetrical symptoms in pregnant women in Japan who had the COVID-19 vaccine up to the second dose. As a booster vaccination is currently underway, further study is needed to improve the management of pregnant women during the current pandemic.
Identifiants
pubmed: 35537777
doi: 10.1111/jog.15285
pmc: PMC9347631
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1561-1569Subventions
Organisme : Ministry of Health, Labor and Welfare of Japan
ID : 20CA2033
Organisme : Subcommittee on Perinatal Infection of the Committee on the Perinatal Period of Japan Society of Obstetrics and Gynecology
Informations de copyright
© 2022 Japan Society of Obstetrics and Gynecology.
Références
Nat Med. 2022 Mar;28(3):504-512
pubmed: 35027756
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
Lancet Reg Health Eur. 2022 Feb;13:100313
pubmed: 35098198
Front Glob Womens Health. 2021 Nov 01;2:761511
pubmed: 34816252
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
J Korean Med Sci. 2021 May 31;36(21):e153
pubmed: 34060261